PARP inhibitors are small molecules designed to inhibit the catalytic activity of PARP enzymes. These inhibitors bind to the NAD+ binding site of PARP, preventing the transfer of ADP-ribose units to target proteins. By inhibiting PARP activity, these compounds can enhance the efficacy of chemotherapy and radiotherapy in cancer treatment, specifically targeting cancer cells' ability to repair DNA damage.
